Pharmafile Logo
Pharmafocus logo
Advanced Search

Gilead

Showing 15 posts of 239 posts found.

Gilead acquires XinThera to strengthen pipeline in oncology and inflammation

May 10, 2023
Sales and Marketing Gilead, Oncology, XinThera, inflammation, oncology

Gilead Sciences has announced the acquisition of all outstanding shares of XinThera, a privately-owned biotech company based in San Diego, …

News
gilead-sciences

‘It’s Time for Trodelvy’: Charity launches petition against Gilead for drug access

July 19, 2021
Sales and Marketing Cancer, Gilead, NHS, charity

The charity Breast Cancer Now has launched a petition calling on Gilead to provide free-of-charge access to its new treatment …

News

Jubilant’s oral remdesivir formulation shows positive results in human trial

April 22, 2021
COVID-19, Gilead, Jubilant Pharma, covid-19 treatment, pharma, pharma news, remdesivir

Jubilant Pharma has announced the successful completion of studies in human volunteers for their oral formulation of remdesivir – an …

News
Gilead sign

Gilead’s bladder cancer drug gets FDA approval

April 15, 2021
FDA, Gilead, bladder cancer, bladder cancer treatment, pharma, pharma news

The FDA have granted accelerated approval to Gilead’s Trodelvy drug for the treatment of metastatic urothelial cancer (UC).

News
Gilead sign

FDA approve Gilead’s breast cancer treatment after Phase III trial

April 8, 2021
FDA, Gilead, Trodelvy, pharma, pharma news

The FDA has approved Gilead’s Trodelvy therapy for the treatment of metastatic triple-negative breast cancer (TNBC).

News
gilead-sciences

Gilead and MSD partner to develop and commercialise two-drug HIV regimen

March 16, 2021
Manufacturing and Production Gilead, HIV, MSD

Gilead and MSD, known as Merck in the US and Canada, have entered into an agreement to co-develop and co-commercialise …

News
gilead-sciences

Galapagos and Gilead halt Phase III trials for idiopathic pulmonary fibrosis drug

February 11, 2021
Gilead

Galapagos and Gilead have halted the ISABELA Phase III clinical studies for their autotaxin inhibitor ziritaxestat in patients with idiopathic …

News
gilead-sciences

NICE recommends rheumatoid arthritis drug Jyseleca for NHS use

January 21, 2021
Gilead, NICE

NICE has issued a final appraisal determination (FAD) recommending the use of Jyseleca (filgotinib) on the NHS in England for …

News

European approval for Kite’s CAR-T therapy Tecartus in elapsed or refractory mantle cell lymphoma

December 17, 2020
Sales and Marketing CAR-T, Europe, Gilead, Kite, Tecartus

Gilead-owned Kite Therapeutics has secured marketing authorisation from the European Commission for its chimeric antigen receptor (CAR) T cell therapy …

News
gilead-sciences

Gilead’s lenacapavir meets primary goal in heavily treated and multidrug resistant HIV-1

November 19, 2020
Research and Development Gilead, HIV, pharma

Gilead has pulled back the curtain on promising new data for its long-acting HIV-1 capsid inhibitor lenacapavir for heavily treated …

News
800px-who_flag_2

WHO warns regulators to consider all available evidence before approving remdesivir for COVID-19

October 26, 2020
Sales and Marketing COVID, COVID-19, Gilead, coronavirus

The World Health Organization’s Chief Scientist Soumya Swaminathan has warned that experts and regulators assessing the use of Gilead’s remdesivir …

News
fdaoutsideweb

FDA approves Gilead’s remdesivir for hospitalised COVID-19 patients

October 23, 2020
Medical Communications, Sales and Marketing COVID-19, FDA, Gilead, remdesivir

The FDA has approved Gilead’s antiviral therapy Veklury (remdesivir) for the treatment of hospitalised COVID-19 patients, making it the first …

News
gilead-sciences

Gilead’s Biktarvy proves non-inferior to standard care for HIV in Black and African American patients

October 22, 2020
Research and Development Biktarvy, Gilead, HIV, pharma

Gilead has revealed promising new Phase 3 data reinforcing the non-inferiority of Biktarvy (bictegravir 50mg/emtricitabine 200mg/tenofovir alafenamide 25mg) compared to …

News
eu_member_flags

European Commission stands by €1bn remdesivir supply deal despite disappointing COVID-19 benefit

October 19, 2020
Manufacturing and Production, Sales and Marketing COVID-19, Europe, Gilead, remdesivir

As Europe continues to face down a rising second wave of COVID-19, the European Commission quickly moved to secure a …

News
shutterstock_2

Gilead to meet rising remdesivir demand in Europe with new supply deal

October 8, 2020
Manufacturing and Production COVID-19, Europe, Gilead

The European Commission (EC) has signed a new joint procurement agreement (JPA) with pharma firm Gilead to improve access to …

News

Latest content

Sanofi shares results for phase 3 LUNA 3 trial in immune thrombocytopenia

April 23, 2024

FDA approves ImmunityBio’s Anktiva bladder cancer treatment

April 23, 2024

EC approves Pfizer’s Emblaveo for multidrug-resistant infection treatment

April 22, 2024

Neurolentech and Kaerus Bioscience enter partnership for research on neurodevelopmental disorder

April 22, 2024

Ardena announces €20m expansion following first GMP approval

April 19, 2024